A Sympathetic Treatment for Obesity.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 32492388.
- Also identified by DOI 10.1016/j.cmet.2020.05.009 and PMC identifier 8142296.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Amphetamine (AMPH), mainly used in the treatment of attention deficit hyperactivity disorder and narcolepsy, has weight loss properties, although with detrimental cardiovascular effects. In this issue, Mahú et al. (2020) describe the effect of a new derivative of AMPH, "PEGyAMPH," a brain-spared anti-obesity drug that alters sympathetic activity without cardiovascular side effects.
Medical subject headings
- Attention Deficit Disorder with Hyperactivity
- Central Nervous System Stimulants